ECSP11011445A - Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c3b - Google Patents

Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c3b

Info

Publication number
ECSP11011445A
ECSP11011445A EC2011011445A ECSP11011445A ECSP11011445A EC SP11011445 A ECSP11011445 A EC SP11011445A EC 2011011445 A EC2011011445 A EC 2011011445A EC SP11011445 A ECSP11011445 A EC SP11011445A EC SP11011445 A ECSP11011445 A EC SP11011445A
Authority
EC
Ecuador
Prior art keywords
antibodies
compositions
methods
directed
complement protein
Prior art date
Application number
EC2011011445A
Other languages
English (en)
Spanish (es)
Inventor
Michael Roguska
Ingo Klagge
Gilbertson Bijan Etemad
Braydon Charles Guild
Yong-In Kim
Igor Splawski
Kehao Zhao
Alexandra Kraus
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP11011445A publication Critical patent/ECSP11011445A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EC2011011445A 2009-05-06 2011-11-08 Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c3b ECSP11011445A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17586009P 2009-05-06 2009-05-06

Publications (1)

Publication Number Publication Date
ECSP11011445A true ECSP11011445A (es) 2012-01-31

Family

ID=43063291

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2011011445A ECSP11011445A (es) 2009-05-06 2011-11-08 Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c3b

Country Status (22)

Country Link
US (1) US20100291106A1 (enExample)
EP (1) EP2427491A2 (enExample)
JP (1) JP2012525829A (enExample)
KR (1) KR20120088551A (enExample)
CN (1) CN102459334A (enExample)
AR (1) AR076655A1 (enExample)
AU (1) AU2010252156A1 (enExample)
CA (1) CA2760757A1 (enExample)
CL (1) CL2011002756A1 (enExample)
CO (1) CO6440515A2 (enExample)
EA (1) EA201101593A1 (enExample)
EC (1) ECSP11011445A (enExample)
IL (1) IL216061A0 (enExample)
MA (1) MA33402B1 (enExample)
MX (1) MX2011011754A (enExample)
PE (1) PE20120899A1 (enExample)
SG (1) SG175432A1 (enExample)
TN (1) TN2011000528A1 (enExample)
TW (1) TW201043638A (enExample)
UY (1) UY32612A (enExample)
WO (1) WO2010136311A2 (enExample)
ZA (1) ZA201107551B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005107708A1 (en) 2004-04-30 2005-11-17 Allergan, Inc. Biodegradable intravitreal tyrosine kinase inhibitors implants
EP2044111B1 (en) 2006-06-21 2014-08-13 MUSC Foundation For Research Development Targeting complement factor h for treatment of diseases
RS20120461A1 (sr) 2009-07-02 2013-06-28 Musc Foundation For Research Development Metode za stimulaciju regeneracije jetre
NZ600393A (en) 2009-11-05 2014-08-29 Alexion Cambridge Corp Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis
MX2012013233A (es) 2010-05-14 2013-05-20 Univ Colorado Regents Grupos que apuntan a receptor 2 de complemento (cr2) mejorados.
CN103249432A (zh) 2010-06-22 2013-08-14 科罗拉多大学董事会,法人团体 补体成分3的C3d片段的抗体
AU2011336702B2 (en) * 2010-11-29 2016-10-06 Novelmed Therapeutics, Inc. Neoantibodies for diagnosing tissue injury
CA2869477C (en) * 2012-04-03 2020-06-09 Novelmed Therapeutics, Inc. Humanized and chimeric anti-factor c3 antibodies and uses thereof
AU2013302441B2 (en) 2012-08-17 2018-05-10 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for detecting complement activation
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
CN104870475B (zh) * 2012-10-25 2019-11-08 美国比奥维拉迪维股份有限公司 抗补体C1s抗体和其用途
CA2889197A1 (en) 2012-11-02 2014-05-08 True North Therapeutics, Inc. Anti-complement c1s antibodies and uses thereof
KR20150088853A (ko) * 2012-11-29 2015-08-03 바이엘 헬스케어 엘엘씨 활성화 단백질 c에 대한 인간화 모노클로날 항체 및 그의 용도
US20160051673A1 (en) 2013-03-29 2016-02-25 Alexion Pharmaceuticals, Inc. Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5
KR101834469B1 (ko) 2013-08-07 2018-03-06 알렉시온 파마슈티칼스, 인코포레이티드 비정형적 용혈성 요독증후군 (ahus) 바이오마커 단백질
CA2926812A1 (en) * 2013-10-07 2015-04-16 Massachusetts Eye And Ear Infirmary Methods of preventing or reducing photoreceptor cell death
JP2017502023A (ja) * 2013-12-24 2017-01-19 ノーベルメッド セラピューティクス インコーポレイテッド． 眼疾患を治療する組成物および方法
SG11201606983SA (en) * 2014-02-27 2016-09-29 Allergan Inc COMPLEMENT FACTOR Bb ANTIBODIES
US11077187B2 (en) 2015-11-17 2021-08-03 Oklahoma Medical Research Foundation Epitope of optimized humanized monoclonal antibodies against activated protein C and uses thereof
CN116554320A (zh) 2016-10-12 2023-08-08 美国比奥维拉迪维股份有限公司 抗C1s抗体及其使用方法
WO2018075474A1 (en) 2016-10-17 2018-04-26 Medical University Of South Carolina Compositions and methods for treating central nervous system injury
TWI833742B (zh) * 2018-04-03 2024-03-01 美商恩格姆生物製藥公司 Ｃ３結合劑及其使用方法
EP3801772A1 (en) * 2018-06-11 2021-04-14 Aarhus Universitet Single domain antibodies for complement regulation
GB2583560A (en) 2018-12-11 2020-11-04 Admirx Inc Fusion protein constructs for complement associated disease
US20240336683A1 (en) * 2021-03-19 2024-10-10 Elpis Biopharmaceuticals Antibodies specific to sialic acid-binding ig-like lectin 15 and uses thereof
WO2024108529A1 (en) * 2022-11-25 2024-05-30 Linno Pharmaceuticals Inc. Properdin binding protein and use thereof
AU2022420788A1 (en) 2021-12-22 2024-05-16 Boehringer Ingelheim International Gmbh Anti-c3 antibodies and antigen-binding fragments thereof and their uses for treating eye or ocular diseases
KR20230105972A (ko) * 2022-01-05 2023-07-12 주식회사 카나프테라퓨틱스 혈관신생 억제제가 결합된 항-C3b 항체 또는 항-C5 항체 및 이의 용도
CN114874329A (zh) * 2022-05-19 2022-08-09 江苏大学 一种补体活化C1s酶荧光检测试剂盒及检测方法与应用
AU2023347940A1 (en) * 2022-09-20 2025-03-27 Visterra, Inc. Treatment of complement mediated diseases and disorders with c3b-antibodies

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE452065B (sv) * 1986-04-11 1987-11-09 Ulf R Nilsson Antikroppspreparation vars antikroppar er specifika for determinanter i c3 b regionen hos denaturerat humant c3 samt dess anvendning och framstellning
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO2001084149A2 (en) * 2000-04-29 2001-11-08 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
US7838165B2 (en) * 2004-07-02 2010-11-23 Kabushiki Kaisha Toshiba Carbon fiber synthesizing catalyst and method of making thereof
WO2006012621A2 (en) * 2004-07-23 2006-02-02 University Of Virginia Patent Foundation Compositions and methods for regulating the alternative pathway of complement
WO2006059108A2 (en) * 2004-12-02 2006-06-08 Domantis Limited ANTI-IL-IRl SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC USES
KR20150139636A (ko) * 2005-10-12 2015-12-11 모르포시스 아게 인간 ｃｄ38에 특이적인 완전 인간 ｈｕｃａｌ ｇｏｌｄ-유도 치료 항체들의 생성 및 프로파일링
GB0613209D0 (en) * 2006-07-03 2006-08-09 Ucb Sa Methods
US8192742B2 (en) * 2007-03-23 2012-06-05 NovelMed Therapeutics Method of inhibiting complement activation with human anti-factor C3 antibodies and use thereof
KR20150029002A (ko) * 2007-06-07 2015-03-17 제넨테크, 인크. 보체-관련 장애의 예방 및 치료를 위한 Ｃ３ｂ 항체 및 방법
CL2008003241A1 (es) * 2007-11-02 2009-07-31 Novartis Ag Molecula de enlace que comprende una porcion de enlace de antigeno que se enlaza con un neoepitopo de c3b; composicion farmaceutica que la comprende; y su uso para tratar trastornos oculares

Also Published As

Publication number Publication date
TW201043638A (en) 2010-12-16
AU2010252156A1 (en) 2011-11-10
CA2760757A1 (en) 2010-12-02
IL216061A0 (en) 2012-01-31
WO2010136311A2 (en) 2010-12-02
CN102459334A (zh) 2012-05-16
UY32612A (es) 2010-12-31
KR20120088551A (ko) 2012-08-08
ZA201107551B (en) 2012-07-25
CL2011002756A1 (es) 2012-03-23
US20100291106A1 (en) 2010-11-18
TN2011000528A1 (en) 2013-05-24
AR076655A1 (es) 2011-06-29
JP2012525829A (ja) 2012-10-25
CO6440515A2 (es) 2012-05-15
EA201101593A1 (ru) 2012-06-29
EP2427491A2 (en) 2012-03-14
WO2010136311A3 (en) 2011-05-26
PE20120899A1 (es) 2012-08-03
MX2011011754A (es) 2011-11-29
SG175432A1 (en) 2011-12-29
MA33402B1 (fr) 2012-07-03

Similar Documents

Publication Publication Date Title
UY32612A (es) Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c3b
CO2018011364A2 (es) Anticuerpos anti-il-33, composiciones, métodos y usos de los mismos
CO7250445A2 (es) Proteínas de unión a antígeno st2
CO6351748A2 (es) Anticuerpos contra il-6 y sus usos
CY1118014T1 (el) Aνti-il-23 αντισωματα
CR20170262A (es) Composiciones y métodos para anticuerpos dirigidos a bmp6
CR20160206A (es) Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento C5
BR112013021562A2 (pt) anticorpos para cd70
MX357678B (es) Moléculas de unión específica a proteína de unión a adn de respuesta transactiva de 43 kda (tdp-43).
BR112012023010A2 (pt) "anticorpo ou fragmento de ligação a antígeno do mesmo que se liga especificamente a cd37, imunoconjugado compreendendo os mesmos, uso dos referidos anticorpo, fragmento e imunoconjugado, composição compreendendo os mesmos, kit, célula isolada, bem como método in vitro para inibir o crescimento de uma célula que expressa cd37"
CR20110358A (es) Proteinas de enlace de miostatina
EA201400579A1 (ru) Антитела к il-36r
EA201790757A1 (ru) Связывающие антиген cd27l белки
CO6290772A2 (es) Anticuerpos dirigidos a angiopoietina 1 y angiopoietina 2 y usos de los mismos
EA201591091A1 (ru) Антигенсвязывающие белки для bcma
EA201791693A1 (ru) Гетеродимерные иммуноглобулины
UA106070C2 (uk) Антитіло, що специфічно зв'язується з egfr і her3
MX382826B (es) Anticuerpos dkk1 y metodos de uso.
UY37030A (es) Anticuerpos dirigidos a cd32b y métodos de uso de los mismos
EA201491214A1 (ru) Композиции и способы применения антител, нацеленных на фактор p
EA201291065A1 (ru) Антитела против vla-4
CL2017002705A1 (es) Anticuerpos que se dirigen a la proteína morfogénica ósea 9 (bmp9) y a los métodos a los que se refieren
BR112013007514A2 (pt) anticorpo isolado, uso da composição e método
EA201500502A1 (ru) Связывающие антиген her3 белки, связывающиеся с бета-шпилькой her3
CO6721048A2 (es) Anticuerpos que se unen a notum pectinacetilesterasa